On World AML Awareness Day, through continued investment in the Trials Acceleration Programme (TAP) network, Cure Leukaemia are proud to announce two major clinical trials are on the horizon, EVOLVE 1 and 2.

Cure Leukaemia’s funding of the Trials Acceleration Programme (TAP) network is accelerating ground-breaking progress in the treatment of Acute Myeloid Leukaemia (AML), with clinical trials offering new hope for patients across the globe.

On the announcement of the EVOLVE trials, Paresh Vyas, Professor of Haematology at the University of Oxford added:

“We are on the cusp of launching two EVOLVE trials in collaboration with HOVON, Dutch hematology trials group, targeting AML patients who cannot undergo chemotherapy – a group for whom treatment options remain limited.

 Additionally, a new intensive chemo trial will open later this year at five TAP Centres and expanding to further centres by the end of 2026. This marks a major advancement in personalising care for AML patients across the spectrum of need.”

Through its ongoing funding of Cure Leukaemia Research Nurses at 15 TAP Centres across the UK, Cure Leukaemia is helping to accelerate international collaboration and cutting-edge research that is shaping the future of AML care.

Professor Charlie Craddock CBE, emphasised the critical role of the charity’s support:

“The funding of clinical trials is the engine room of progress for AML patients. Cure Leukaemia’s support of the TAP network ensures we can rapidly deliver innovative treatments to those who urgently need them. It’s this international collaboration that will transform outcomes for blood cancer patients across the globe.”

The TAP network is primarily funded by Cure Leukaemia’s Tour 21 event, which see’s a team of amateur riders ride all 21 stages of the Tour de France one week ahead of the professionals. From Israel to the UK, patients are not only benefiting from Cure Leukaemia’s work – they are giving back to support with Roy Lowenberg, an AML patient from Israel and part of the Tour 21 2025 team.

“Riding the Tour de France is my way of giving back – to help more people like me get the second chance they deserve.”

On World AML Awareness Day, Cure Leukaemia’s investment in the TAP network is making a measurable, global impact – connecting science, patients, and hope across borders. With more trials on the horizon, the future for AML patients worldwide is brighter than ever.